A venous malformation is a slow-flow vascular anomaly made up of abnormally formed veins that are present from birth, even if they aren’t noticed until months or years later. They are the most common type of congenital vascular anomaly, and unlike hemangiomas, which tend to grow rapidly in infancy and then shrink on their own, venous malformations never regress spontaneously. They grow proportionally with the body and often worsen over a lifetime, driven by hormonal shifts, trauma, or incomplete treatment. The biology behind them has become far clearer in the last two decades, and that understanding is beginning to change how they are treated.
What a Venous Malformation Actually Is
Under a microscope, a venous malformation consists of irregularly shaped, dilated channels lined by a thin layer of flat endothelial cells. The smooth muscle that normally wraps around a vein and gives it structure is often missing or far too thin relative to the size of the channel. These misshapen channels vary in size and can appear randomly distributed, clustered, or packed tightly together. Blood pools inside them, and the sluggish flow commonly leads to clotting within the channels. Pathologists frequently see small blood clots and a reactive pattern called papillary endothelial hyperplasia inside these lesions.1Clinics in Plastic Surgery. Histopathology of Vascular Anomalies – Section: Venous Malformation
Because the walls are so thin and the flow so slow, venous malformations behave differently from normal veins. They swell when the affected body part hangs down (dependent positioning) or during physical exertion. Over time, the stagnant blood within them can calcify into small, round, stone-like deposits called phleboliths, which sometimes show up on an X-ray and can be a helpful diagnostic clue.
How They Present and When They’re Noticed
Although venous malformations are present at birth, they aren’t always visible right away. In one study, the average age when a venous malformation was first noticed was about seven years old. Those that sit deeper in muscle tissue tend to be discovered later than ones in the skin or just beneath it: only about a quarter of intramuscular venous malformations were apparent at birth, compared with roughly half of superficial ones.2PubMed. Early versus later presentations of venous malformations: where and why? The most common signs include soft tissue swelling, a compressible mass, pain, and bluish skin discoloration. Intramuscular lesions are more frequently painful, more likely to contain phleboliths, and more often limit exercise.
Venous malformations can appear almost anywhere on the body, including the head and neck, trunk, extremities, and internal organs. Their clinical impact varies enormously. A small, superficial lesion on the forearm might cause nothing more than a cosmetic concern, while a large, deep lesion infiltrating the muscles and joints of a leg can produce chronic pain, swelling, stiffness, and progressive loss of function.
Progression Over a Lifetime
One of the most important things to understand about venous malformations is that they tend to worsen. A study tracking children with venous malformations found that roughly a quarter showed progression before adolescence, about three-quarters progressed before reaching adulthood, and over 90 percent progressed at some point over their lifetime. Adolescence was a particularly risky window, with progression rates roughly two and a half times higher than in younger children. Diffuse lesions expanded more often than localized ones, and malformations on the extremities and trunk worsened more frequently than those on the head and neck.3Annals of Plastic Surgery. Venous Malformation: Risk of Progression During Childhood and Adolescence
Pregnancy is another well-documented trigger. A nationwide study found that nearly half of women with vascular malformations experienced symptom worsening during pregnancy, and a similar proportion reported that their lesion increased in volume. Women who had already experienced puberty-related symptom progression were at higher risk of pregnancy-related worsening.4BJOG: An International Journal of Obstetrics and Gynaecology. Complications of Pregnancy and Birth in Women With Vascular Malformations: A Nationwide Cross-Sectional Study The connection to hormonal changes is consistent with the adolescence data and helps explain why some lesions seem stable for years before suddenly enlarging.
The Genetics Behind the Malformation
Most venous malformations are sporadic, meaning they aren’t inherited from a parent. Instead, they arise from mutations that occur in a small number of cells during embryonic development. The two best-understood genetic culprits are the TIE2 receptor gene (also called TEK) and the PIK3CA gene.
Somatic mutations in TEK have been found in about half of sporadic venous malformations tested. These mutations weren’t present in the patients’ blood or normal tissue, confirming they arose locally. They produce a hyperactive version of the TIE2 receptor that stays switched on without its normal signal, triggering downstream changes that disrupt blood vessel formation and the endothelial cell layer.5PubMed Central. Somatic mutations in angiopoietin receptor gene TEK cause solitary and multiple sporadic venous malformations Further work showed that these TIE2 mutations chronically activate a signaling cascade that leads to deficiency in a key structural protein called fibronectin, contributing to the fragile, malformed vessel walls characteristic of the condition.6PubMed Central. Common and specific effects of TIE2 mutations causing venous malformations
In venous malformations that lack TEK mutations, activating mutations in PIK3CA and related genes of the PI3K/AKT signaling pathway account for roughly 30 percent of cases.7PubMed Central. Somatic PIK3CA mutations as a driver of sporadic venous malformations PIK3CA mutations cause endothelial cells to proliferate excessively and reduce the coverage of pericytes, the support cells that normally stabilize blood vessel walls.8PubMed Central. Somatic activating mutations in Pik3ca cause sporadic venous malformations in mice and humans These two genetic pathways, TEK and PIK3CA, appear to be mutually exclusive in a given lesion, but they converge on similar downstream effects: chronic overactivation of AKT, disrupted angiogenesis, and abnormal endothelial cell behavior.9American Journal of Human Genetics. Somatic Activating PIK3CA Mutations Cause Venous Malformation
Understanding these genetic drivers matters because it has opened the door to targeted drug therapy, which we’ll get to shortly.
Diagnosis and Imaging
A skilled clinician can often suspect a venous malformation based on history and physical exam alone: the characteristic bluish, soft, compressible mass that swells with gravity or straining is fairly distinctive. But imaging confirms the diagnosis and maps the extent of the lesion before any treatment is planned.
Doppler ultrasound is typically the first imaging study. It shows either no detectable flow or very slow venous flow within the lesion, helping to distinguish a venous malformation from high-flow lesions like arteriovenous malformations. For pretreatment planning, MRI is the gold standard. Venous malformations appear dark on T1-weighted images and very bright on T2-weighted images, with variable enhancement after contrast injection.10PubMed. Soft-tissue venous malformations in adult patients: imaging and therapeutic issues MRI also reveals how deeply the lesion extends into muscle, bone, or joints, information that is critical for deciding between sclerotherapy, surgery, or conservative management.
Phleboliths seen on imaging are a useful marker. One study found that the presence of more than two phleboliths was the strongest indicator that the venous malformation also had tiny arteriovenous connections (microshunts), a feature that can influence the treatment approach.11PubMed. Venous Malformations: Phleboliths Correlate With the Presence of Arteriovenous Microshunts
The Coagulopathy Problem
One of the lesser-known but clinically significant aspects of venous malformations is localized intravascular coagulopathy, or LIC. The slow, stagnant blood flow within these malformed channels triggers chronic low-grade clotting. This consumes clotting factors locally and shows up on blood tests as elevated D-dimer levels. In more severe cases, fibrinogen drops and other clotting factors become depleted, sometimes accompanied by a mild drop in platelet counts.12PubMed. Localized intravascular coagulation in venous malformations: A system review
LIC is more common in larger lesions. In a study looking at risk factors, large surface area and palpable phleboliths were independently associated with elevated D-dimer levels, and severe LIC with low fibrinogen was linked to extensive malformations of the extremities.13PubMed Central. Association of localized intravascular coagulopathy with venous malformations This matters for two practical reasons. First, ongoing LIC can cause chronic pain from repeated small thromboses within the lesion. Second, and more dangerously, events like surgery, sclerotherapy, prolonged immobilization, or pregnancy can tip LIC into full-blown disseminated intravascular coagulation (DIC), a life-threatening condition where widespread micro-clotting depletes clotting factors throughout the body and causes both clotting and uncontrolled bleeding simultaneously.14PubMed. Coagulation abnormalities associated with extensive venous malformations of the limbs: differentiation from Kasabach-Merritt syndrome This is why specialists check D-dimer and fibrinogen levels before any procedure on a venous malformation and may prescribe preventive blood-thinning medication beforehand.
Sclerotherapy
For many venous malformations, the first-line procedural treatment is sclerotherapy: injecting a chemical agent directly into the malformed channels to destroy their lining and cause them to scar shut. Several different sclerosants are used, each with its own tradeoff between effectiveness and side effects.
Ethanol (absolute alcohol) has historically been one of the most effective agents at shrinking venous malformations, but it also carries the highest complication rate. A systematic review and network meta-analysis confirmed that ethanol showed statistically better response rates than most other agents, but also the highest incidence of complications.15PubMed. A systematic review and network meta-analysis of the effectiveness of sclerotherapy for venous malformation Common complications of sclerotherapy generally include skin damage (the most frequent), and rarer but more serious problems like nerve injury, muscle damage, and in unusual cases, pulmonary embolism.16PubMed. Outcomes and complications of sclerotherapy for venous malformations
Because of ethanol’s toxicity, there has been growing interest in alternatives that balance efficacy with safety. A network meta-analysis of 22 randomized trials involving over 1,800 patients ranked bleomycin, polidocanol, and their combinations among the treatments offering the best balance of effectiveness and safety.17Chinese Journal of Plastic and Reconstructive Surgery. Efficacy and safety of sclerosants in the treatment of venous malformations: A network meta-analysis of randomized controlled trials More recently, bleomycin-polidocanol foam has shown treatment efficacy comparable to ethanol with a trend toward fewer severe side effects.18PubMed Central. Comparison of bleomycin polidocanol foam versus absolute ethanol for sclerotherapy of venous malformations Multiple sessions are usually required, and sclerotherapy rarely eliminates a venous malformation entirely. The realistic goal for most patients is shrinking the lesion enough to relieve pain and improve function.
Surgery and Other Local Treatments
Surgical excision is considered when a venous malformation is well-defined enough to be removed without sacrificing critical structures, or when it causes symptoms that sclerotherapy hasn’t adequately controlled. In one surgical series, complete resection was achieved in just over half of operated cases, with nerve infiltration being the main reason surgery was cut short.19PubMed Central. Outcome after surgical treatment of venous malformations of the hand in childhood A larger study of 48 patients undergoing excision or debulking found that about three-quarters experienced remission or improvement, though recurrence after radical excision occurred in about 10 percent and regrowth after debulking was seen in roughly a quarter of cases.20Annals of Vascular Surgery. The results of surgical treatment for patients with venous malformations
For superficial venous malformations with significant skin involvement, Nd:YAG laser therapy can help reduce discoloration and shrink surface components.21PubMed. Vascular malformations (II). Diagnosis, pathology and treatment Laser therapy is generally used as a complement to sclerotherapy or surgery rather than as a standalone treatment for anything more than superficial lesions. Compression garments remain a cornerstone of conservative management, reducing swelling and protecting against thrombotic episodes, especially in extremity lesions.
Drug Therapy and Targeted Molecular Treatments
The discovery of the genetic drivers behind venous malformations has created an entirely new treatment avenue. Sirolimus (also known as rapamycin), a drug originally used to prevent organ transplant rejection, inhibits the mTOR pathway, which sits downstream of both the TIE2 and PIK3CA signaling cascades. A systematic review found that oral sirolimus produced some level of clinical improvement in about 72 percent of patients, with consistent relief in pain, coagulopathy, and bleeding. However, actual shrinkage of the malformation varied, and some patients experienced side effects significant enough to limit treatment.22PubMed. Sirolimus for Venous Malformations: A Systematic Review of Efficacy and Safety Sirolimus has been particularly useful for deep or diffuse venous malformations that are poor candidates for sclerotherapy or surgery.
Even more targeted is alpelisib, a PI3K-alpha inhibitor originally developed as a cancer drug. A systematic review of 47 patients with genetically confirmed venous malformations treated with alpelisib found that 77 percent achieved a partial or complete radiological response, and 98 percent reported symptomatic improvement.23PubMed. Alpelisib for TEK- and PIK3CA-Related Venous Malformations: A Systematic Review Early case reports in patients with TIE2 mutations specifically have shown control of pain, improvement in walking, reduction in the abnormal venous network, and dramatic improvement in coagulopathy.24PubMed. Repurposing alpelisib, an anti-cancer drug, for the treatment of severe TIE2-mutated venous malformations: Preliminary pharmacokinetics and pharmacodynamic data These are still early days, and large randomized trials are needed, but the shift toward genotype-guided therapy is one of the most promising developments in the field.
Quality of Life and the Long-Term Burden
Venous malformations take a measurable toll on quality of life. A meta-analysis comparing people with vascular malformations to the general population found significantly lower scores in bodily pain and mental health domains.25PubMed Central. Vascular Malformations and Health-Related Quality of Life: A Systematic Review and Meta-analysis Pain is the most consistent complaint, driven by chronic thrombosis within the lesion, swelling with activity, and the mechanical effects of an expanding mass on surrounding tissues. The cosmetic impact shouldn’t be underestimated either. Visible lesions on the face or hands can affect self-esteem and social interactions, particularly during adolescence when the malformations often worsen.
A prospective study that followed patients over time found that quality-of-life scores in the physical pain and physical limitation domains actually improved at follow-up, and no domain deteriorated. Interestingly, whether patients received invasive treatment or not was not associated with long-term quality-of-life change. Female sex, muscle or bone involvement, and older age were the factors most associated with positive shifts in certain quality-of-life domains over time.26Journal of Plastic, Reconstructive & Aesthetic Surgery. Long-term health-related quality of life in patients with vascular malformations: A prospective observational study The finding that invasive treatment didn’t clearly separate the long-term quality-of-life trajectories is worth sitting with. It doesn’t mean treatment is pointless, since treatment often targets specific symptoms like pain or functional limitation. But it does suggest that the condition’s overall burden on life is driven by factors beyond what any single procedure can fix.
Conditions That Look Similar
Venous malformations are sometimes confused with glomuvenous malformations (formerly called glomangiomas). Though both produce bluish skin lesions, they differ in several ways. Glomuvenous malformations tend to be more superficial, feel firmer and less compressible, and are often painful on palpation. The genetic basis is entirely distinct: glomuvenous malformations are caused by loss-of-function mutations in the glomulin gene, while venous malformations arise from gain-of-function mutations in TIE2 or PIK3CA.27JAMA Dermatology. Glomuvenous Malformation (Glomangioma) and Venous Malformation: Distinct Clinicopathologic and Genetic Entities Distinguishing between the two matters because glomuvenous malformations don’t carry the same coagulopathy risk and respond differently to treatment.
Infantile hemangiomas are the other major source of confusion, but the distinction is usually straightforward once you know what to look for. Hemangiomas appear in the first weeks of life, grow rapidly over months, and then slowly involute over years. Venous malformations are present from birth, grow with the child, and never involute. The treatment strategies are completely different.
Syndromic Venous Malformations
Most venous malformations are isolated lesions. In rare cases, they appear as part of a broader syndrome. Blue rubber bleb nevus syndrome (also called Bean syndrome) is perhaps the best known, characterized by numerous venous malformations on the skin and within the gastrointestinal tract.28PubMed. Venous malformations in blue rubber bleb nevus syndrome: variable onset of presentation The gastrointestinal lesions can bleed chronically, leading to iron-deficiency anemia that sometimes requires blood transfusions. This syndrome has also been traced to somatic TIE2 mutations, connecting it genetically to common sporadic venous malformations.29PubMed. Blue Rubber Bleb Nevus (BRBN) Syndrome Is Caused by Somatic TEK (TIE2) Mutations Venous malformations in this syndrome can appear in unusual locations, including the eye socket.30PubMed. Postural changes revealing orbital venous malformation using ultrasound in blue rubber bleb nevus syndrome
When venous malformations affect the extremities extensively, they can sometimes interfere with limb growth, typically causing slight undergrowth rather than overgrowth, along with progressive muscle wasting around the affected area.31PubMed. Vascular anomalies and the growth of limbs: a review This distinguishes them from certain other vascular anomaly syndromes, such as Klippel-Trénaunay syndrome, where limb overgrowth is the more typical pattern. Any child with a venous malformation involving a limb should have growth monitored, since even a small discrepancy in leg length can affect gait and spinal alignment over time.